Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Elo Mutual Pension Insurance Co

Elo Mutual Pension Insurance Co increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 25.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,888 shares of the medical equipment provider’s stock after acquiring an additional 5,197 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Hologic were worth $1,866,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. General Partner Inc. bought a new position in shares of Hologic during the 4th quarter valued at about $26,000. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. Finally, Smithfield Trust Co lifted its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 1.6 %

NASDAQ HOLX opened at $61.32 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The firm’s fifty day simple moving average is $65.24 and its 200-day simple moving average is $73.29. The company has a market capitalization of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of a number of recent research reports. Stephens restated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Finally, Raymond James restated an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.